Anthera Pharmaceuticals   Report issue

For profit Phase 3 Phase 4
Founded: Hayward CA United States (2004)
Status: Defunct (2018)

Organization Overview

First Clinical Trial
2004
NCT00095732
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 4 Trials (1)

altu-135 (8 trials)

Drugs in Phase 3 Trials (3)

blisibimod (9 trials)

pancreatin (2 trials)

varespladib methyl ester (9 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Chest Syndrome (Phase 2)

Acute Coronary Syndrome (Phase 3)

Anemia, Sickle Cell (Phase 2)

Coronary Artery Disease (Phase 2)

Coronary Disease (Phase 2)

Cystic Fibrosis (Phase 4)

Exocrine Pancreatic Insufficiency (Phase 4)

Fibrosis (Phase 4)

Glomerulonephritis, IGA (Phase 3)

Granulomatosis with Polyangiitis (Phase 2)

Kidney Diseases (Phase 3)

Lupus Erythematosus, Systemic (Phase 3)

Microscopic Polyangiitis (Phase 2)

Myocardial Ischemia (Phase 2)

Nephritis (Phase 3)

Purpura (Phase 3)

Purpura, Thrombocytopenic (Phase 3)

Purpura, Thrombocytopenic, Idiopathic (Phase 3)

Renal Insufficiency (Phase 1)

Syndrome (Phase 3)

Systemic Vasculitis (Phase 2)

Vasculitis (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 26
  • # of Trial APIs: 4